CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc.

1:16-cv-00540

Overview

Case Number 1:16-cv-00540
Filing Date 2016-06-29
Status Terminated
Termination Date 2018-08-21
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sanofi-Aventis U.S. LLC Operating Company

Represented By

10 Attorneys Listed

Nicole E. Grimm

Email: grimm@mbhb.com

Daniel F. Gelwicks

Email: dgelwicks@steptoe.com

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Kurt W. Rohde

Email: rohdek@mbhb.com

Jeremy E. Noe

Email: noe@mbhb.com

James L Lovsin

Email: lovsin@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen Riesenburger Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

10 Attorneys Listed

Nicole E. Grimm

Email: grimm@mbhb.com

Daniel F. Gelwicks

Email: dgelwicks@steptoe.com

Paula S. Fritsch

Email: pfritsch@amgen.com

Paul H. Berghoff

Email: berghoff@mbhb.com

Kurt W. Rohde

Email: rohdek@mbhb.com

Jeremy E. Noe

Email: noe@mbhb.com

James L Lovsin

Email: lovsin@mbhb.com

Alison J. Baldwin

Email: baldwin@mbhb.com

Jeffrey B. Bove

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Karen Riesenburger Poppel

RatnerPrestia, P.C.

Tel: +1 (302) 778-2500

1007 Orange Street, Suite 205, P.O. Box 1596

Counter Claimant

Zydus Pharmaceuticals (USA) Inc. Operating Company

Represented By

5 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Edward M. Mathias

Email: tmathias@axinn.com

David K. Ludwig

Email: dludwig@axinn.com

Dan Feng Mei

Email: dmei@axinn.com

Chad A. Landmon

Email: clandmon@axinn.com

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials Counterparts in force
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): ๐Ÿ‡บ๐Ÿ‡ธ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7897590
Methods to mobilize progenitor/stem cells
Filed: 2007-08-20
Issued: 2011-03-01
Expired (Term Ended)
Expires: 2024-11-16
US6987102
Methods to mobilize progenitor/stem cells
Filed: 2002-07-30
Issued: 2006-01-17
Expired (Term Ended) +357d PTA
Expires: 2023-07-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. ยง 283) Statutorily Barred

Statutorily Barred โ€” Patent expired. Under 35 U.S.C. ยง 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term โ€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. ยง 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

5

Dispositive

0

Granted

0

Denied

0

Pending / Review

5

Motions by Category

Claim Construction / Markman Filing 1 Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME and amend scheduling order to (See Stipulation) - filed by Zydus Pharmaceuticals (USA) Inc.. (Gattuso, Dominick) (Entered: 07/2...
Entry #60 • 2017-07-25 Document →
Procedural / Extension Motion Pending / Under Review
Letter to The Honorable Gregory M. Sleet from Dominick T. Gattuso regarding Reply to Plaintiffs' Response to Defendant's Request for Leave to File a Summary Jud...
Entry #35 • 2017-04-28 Document →
Procedural / Extension Motion Pending / Under Review
Letter to The Honorable Gregory M. Sleet from Jeffrey B. Bove regarding Response to Zydus' Request for Leave to File a Summary Judgment Motion - re 32 Letter,. ...
Entry #33 • 2017-04-25 Document →
Procedural / Extension Motion Pending / Under Review
[SEALED] Letter to The Honorable Gregory M. Sleet from Dominick T. Gattuso regarding Request for Leave to File a Summary Judgment Motion. (Attachments: # 1 Exhi...
Entry #32 • 2017-04-20 Document →
Claim Construction / Markman Filing Pending / Under Review
STIPULATION Regarding the Scheduling Order re deletion of paragraph 4 pertaining to claim construction by Genzyme Corporation, Sanofi-Aventis U.S. LLC. (Attachm...
Entry #23 • 2016-11-02 Document →

Docket Entries

(120 total)
Pleading / Complaint

COMPLAINT filed against Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1955844.) - filed by Genzyme Corporation, Sanofi-Aventis U.S. LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(sar) (Entered: 06/29/2016)

Entry #1 • 2016-06-29
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 06/29/2016)

Entry #2 • 2016-06-29
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 18, 2016. Date of Expiration of Patent: July 22, 2023.Thirty Month Stay Deadline: 11/18/2018. (sar) (Entered: 06/29/2016)

Entry #3 • 2016-06-29
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,897,590 B2; US 6,987,102 B2;. (sar) (Entered: 06/29/2016)

Entry #4 • 2016-06-29
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Genzyme Corporation, Sanofi-Aventis U.S. LLC filed by Genzyme Corporation, Sanofi-Aventis U.S. LLC. (Bove, Jeffrey) (Entered: 06/29/2016)

Entry #5 • 2016-06-29
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc